Voluntary announcement - the clinical trial approval for HS-20197 for injection issued by the national medical products administration
Filed with HKEX · Stock code 3692 · · 1 page · English
Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 3692) VOLUNTARY ANNOUNCEMENT THE CLINICAL TRIAL APPROVAL FOR HS-20197 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION The board of directors (the “Board”) of Hansoh Pharmaceutical Group Company Limited (the “Company” and together with its subsidiaries
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Hansoh Pharmaceutical Group: Wclc 2026 | hansoh pharma announces proffered oral presentation of phase i study data of HS-10370 combined with adebrelimab and chemotherapy in advanced kras G12C-mutated nsclc
- Hansoh Pharmaceutical Group: 2026 Wclc | hansoh pharma announces interim results from phase 3 artemis-008 study of risvutatug rezetecan (HS-20093) in patients with relapsed small cell lung cancer
- Biologics license application of risvutatug rezetcan (HS-20093) for injection for small cell lung cancer accepted by the nmpa
- Hansoh Pharmaceutical Group: Pharma announces artemis-011 phase 3 trial of risvutatug rezetecan (HS-20093) met primary endpoint of irc-assessed PFS in osteosarcoma
- Hansoh Pharmaceutical Group: A mark of excellence!hansohpharmaceutical secures a top three spot among "model industrial enterprises for china’s pharmaceutical R&D pipelines" for the tenth consecutive year.
Later from Hansoh Pharmaceutical
- Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints
- Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
- Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
- Interim report 2026
- Notification letter to registered shareholders and reply form
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical